Summary of responses for 52 patients by cohort and maximum dose received (data including 58 unique and re-enrolled patients are included in parentheses)
| Response . | Cohort . | Total . | Max dose level, mg/m2 . | |||||
|---|---|---|---|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | 30+30 . | 40+40 . | 30+50 . | ||
| NE | 1 | 1 | 3 | 1 | 6 | 5 | 1 | 0 |
| PD | 6 | 0 | 1 | 4 | 11 | 6 | 0 | 5 |
| SD | 5 | 1 | 4 | 4 (5) | 14 (15) | 6 | 1 | 7 (8) |
| PR | 8 | 1 | 9 (11) | 3 (6) | 21 (26) | 9 (10) | 1 | 11 (15) |
| Total | 20 | 3 | 17 (19) | 12 (16) | 52 (58) | 26 (27) | 3 | 23 (28) |
| PR% | 40 | 33 | 53 (58) | 25 (38) | 40 (45) | 35 (37) | 33 | 48 (54) |
| Response . | Cohort . | Total . | Max dose level, mg/m2 . | |||||
|---|---|---|---|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | 30+30 . | 40+40 . | 30+50 . | ||
| NE | 1 | 1 | 3 | 1 | 6 | 5 | 1 | 0 |
| PD | 6 | 0 | 1 | 4 | 11 | 6 | 0 | 5 |
| SD | 5 | 1 | 4 | 4 (5) | 14 (15) | 6 | 1 | 7 (8) |
| PR | 8 | 1 | 9 (11) | 3 (6) | 21 (26) | 9 (10) | 1 | 11 (15) |
| Total | 20 | 3 | 17 (19) | 12 (16) | 52 (58) | 26 (27) | 3 | 23 (28) |
| PR% | 40 | 33 | 53 (58) | 25 (38) | 40 (45) | 35 (37) | 33 | 48 (54) |
NE indicates nonevaluable; PD, progressive disease; SD, stable disease; and PR, partial response.